Excreted Unchanged %
Hepatic (renal)
Half-Life (Normalesrd) Hours
2-3/Unchanged
Plasma Protein Binding %
80-90
Volume Of Distribution L/Kg
0.1-0.2
Dose For Normal Renal Function
650 mg q4h
Adjustment For Renal Failure Method
I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
q4h [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
q4-6h [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis
Supplement For Dialysis [Recommendation Level]: Pd
PD: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Clissold SP. Aspirin and related derivatives of salicylic acid. Drugs. 1986; 32 Suppl 4: 8-26. [PMID: 3552588] / Montgomery PR, Berger LG, Mitenko PA, Sitar DS. Salicylate metabolism: effects of age and sex in adults. Clin Pharmacol Ther. 1986; 39: 571-6. [PMID: 3698465] / Montgomery PR, Sitar DS. Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets. Biopharm Drug Dispos. 1986; 7: 21-5. [PMID: 3955197] / Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet. 1985; 10: 164-77. [PMID: 3888490]
Toxicity Notes
Nephrotoxic in high doses. May decrease GFR when renal blood flow is prostaglandin dependent. Excretion enhanced in alkaline urine. May add to uremic gastrointestinal and hematologic symptoms. Protein binding reduced in ESRD. 5% excreted unchanged in acidic urine, 85% in alkaline urine.